August 2016August 2016
New Product - Lonquex
Lonquex (lipegfilgrastim (rbe)) is a long acting form of recombinant human granulocyte colony stimulating factor (G‑CSF). Human G‑CSF is a glycoprotein that regulates the production and release of functional neutrophils from the bone marrow. Filgrastim is an unglycosylated recombinant methionyl human G‑CSF. Lipegfilgrastim is a sustained duration form of filgrastim due to decreased renal clearance. Lipegfilgrastim binds to the human G‑CSF receptor like filgrastim and pegfilgrastim. Lonquex is indicated for reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes). Lonquex is contraindicated in patients with known hypersensitivity to other G‑CSF products including lenograstim, pegfilgrastim and filgrastim. Lonquex is available as a single use prefilled glass syringe containing a solution volume of 0.6 mL with 6 mg of lipegfilgrastim, for a 10 mg/mL solution in packs of 1’s.
Copyright © MIMS Australia Pty Ltd. All rights reserved.
MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au